Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Thierry Berghmans
*
, Valerie Durieux
,
Lizza E. L. Hendriks
, Anne-Marie Dingemans
*
Corresponding author for this work
Pulmonologie
MA Med Staf Spec Longziekten
GROW - Innovative Cancer Diagnostics & Therapy
Research output
:
Contribution to journal
›
(Systematic) Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Programmed Death-ligand 1 (PD-L1)
100%
Nivolumab
100%
Pembrolizumab
100%
Atezolizumab
100%
Clinically Significant
50%
Best Medical Treatment
50%
Chemotherapy
50%
Monotherapy
50%
Overall Survival
50%
Prospective Randomized Trial
50%
Meta-analysis
50%
Quality of Life Impact
50%
Clinical Analysis
50%
Clinical Improvement
50%
Treatment Duration
50%
Non-small Cell Lung Cancer (NSCLC)
50%
Docetaxel
50%
Unselected Patients
50%
Checkpoint Inhibitors
50%
New Targets
50%
Phase II Study
50%
Lung Cancer Treatment
50%
Positive Impact
50%
Incremental Cost
50%
Improved Survival
50%
Metastatic Non-small Cell Lung Cancer
50%
Rapid Progression
50%
Cost per QALY
50%
Ipilimumab
50%
Cytotoxic T Lymphocytes
50%
New Combination
50%
First-line Pembrolizumab
50%
Anti-programmed Death 1
50%
Long History
50%
Platinum Doublets
50%
INIS
patients
100%
cancer
100%
immunotherapy
100%
lung cells
100%
data
50%
antibodies
25%
levels
25%
lungs
25%
comparative evaluations
25%
cost
25%
quality of life
25%
death
25%
failures
25%
chemotherapy
25%
platinum
25%
metastases
25%
lymphocytes
25%
ligands
25%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Pembrolizumab
75%
Nivolumab
50%
Programmed Death-Ligand 1
50%
Atezolizumab
50%
Health Care Cost
25%
Quality of Life
25%
Meta-Analysis
25%
Overall Survival
25%
Lung Cancer
25%
Monotherapy
25%
Quality Adjusted Life Year
25%
Treatment Duration
25%
Cancer Therapy
25%
Cytotoxic T-Cell
25%
Docetaxel
25%
Ipilimumab
25%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Pembrolizumab
75%
Nivolumab
50%
Atezolizumab
50%
Overall Survival
25%
Lung Cancer
25%
Monotherapy
25%
Chemotherapy
25%
Docetaxel
25%
Ipilimumab
25%